DR CONGO TELLS USA: FINALLY START TESTS ON PROMISING EBOLA MONOCLONAL TREATMENT USING ANTIBODIES FROM EBOLA SURVIVORS, EFFECTIVE THERAPY KNOWN SINCE THE 1990s, HAS BEEN DROPPED FROM CLINICAL TRIALS BY PUSHERS OF RISKY VACCINES


From media

Use of a new experimental Ebola treatment
• The Ministry of Health has asked the US authorities to test the mAB114 treatment in the context of the current outbreak.
• mAB114 is an antibody derived from the research that Professor Jean-Jacques Muyembe of the National Institute for Biomedical Research has done on the basis of the serum of a survivor of the Ebola epidemic of Kikwit in 1995. This research started there is 3 years old.
• In order to test the effectiveness of the treatment, they did tests on monkeys to which they injected the Ebola virus. All monkeys treated with mAB114 were cured.
• The effective use of this antibody in the Democratic Republic of Congo will depend on the approval of the ethics committee of the School of Public Health of the University of Kinshasa.

https://us13.campaign-archive.com/?u=89e5755d2cca4840b1af93176&id=76c24e86b4

Mise au point du ministère de l’an sante
Le Ministère de la Santé a fait la demande aux autorités américaines de tester le traitement mAB114 dans le cadre de l’épidémie actuelle.
mAB114 est un anticorps issu des recherches que le Professeur Jean-Jacques Muyembe de l’Institut National de Recherche Biomédicale a faite sur base du sérum d’un survivant de l’épidémie d’Ebola de Kikwit en 1995. Ces recherches ont commencé il y a 3 ans.
Afin d’expérimenter l’efficacité du traitement, Ils ont fait des tests sur des singes auxquels ils ont injecté le virus Ebola. Tous les singes ayant reçu le traitement mAB114 ont été guéris.
L’utilisation effective de cet anticorps en République Démocratique du Congo dépendra de l’approbation du comité d’éthique de l’Ecole de Santé Publique de l’Université de Kinshasa.

https://actualite.cd/2018/05/24/rdc-ebola-le-ministere-de-la-sante-envisage-lutilisation-dun-nouveau-traitement-experimental-contre-ebola/

 

“This study adds to NIAID efforts in conducting scientifically and ethically sound biomedical research to develop countermeasures against Ebola virus disease,” added Dr. Fauci.

MAb114 is a monoclonal antibody — a protein that binds to a single target on a pathogen — isolated from a human survivor of the 1995 Ebola outbreak in Kikwit, a city in the DRC. Nancy Sullivan, Ph.D., chief of the Biodefense Research Section in NIAID’s Vaccine Research Center (VRC), and her team, in collaboration with researchers from the National Institute of Biomedical Research (INRB) in the DRC and the Institute for Biomedical Research in Switzerland, discovered that the survivor retained antibodies against Ebola 11 years after infection. They isolated the antibodies and tested the most favorable ones in the laboratory and non-human primate studies, and selected mAb114 as the most promising. Professor Jean-Jacques Muyembe, director general of INRB and one of the scientists involved in the original detection of the Ebola virus in 1976, played a key role in discovering mAb114.

https://www.nih.gov/news-events/news-releases/nih-begins-testing-ebola-treatment-early-stage-trial

Comments are closed.

%d bloggers like this: